Sotex PharmFirm is the basis of the production segment of the PROTEK Group. Sotex is one of Russia’s the most high-tech and innovative pharmaceutical enterprises.
Sotex PharmFirm – high-tech EU GMP certified manufacturer. The plant located
in Sergiev Posad district of Moscow region accomplishes full production cycle:
preparation of injection solutions, filling of ampoules and syringes, and then
labeling, packaging and shipment to the warehouse. All manufacturing
processes are performed in strict compliance with the international
requirements on the equipment of leading European concerns.
The company benefits from an in-house R&D unit. Using advanced equipment
and first class human resources, the unit develops a wide product range
including biotechnical formulations.
In 2016 the ampoule production of Sotex received the European GMP
certificate. This certificate was issued by the Portuguese National Institute of Pharmacy and Medicines. Successful passing of the certification procedure for compliance with European GMP standards is the result of many years of work
on the organization of production and the introduction of a modern quality
management system. The presence of the European GMP certificate puts Sotex
on a par with the world's leading manufacturers and allows the company to
adequately represent Russia on the international market.
Partnerships with foreign pharmaceutical manufacturers are one of the most
important components of the PROTEK Group production segment business
activity. Sotex takes pride in its unique experience of cooperation with world’s
pharmaceutical industry leaders in the field of licensed manufacture and
promotion of ready formulations. The company offers a full range of services,
from registration, production, and distribution of medicines to retail sales. It
also offers extensive marketing support and assistance.
We provide our foreign partners with practical solutions, which speed up and
facilitate localization of the manufacturing process in Russia in full compliance
with EU GMP standards.
Advantages of such a partnership have already been appreciated by many
leading pharmaceutical companies: Sanofi, Bayer, Takeda, Novartis, Sandoz,
Commercialization of innovative and high-tech products
The company’s product portfolio includes more than 150 popular items, which have won the trust of specialists and consumers, as well as drugs used in socially significant areas of medical treatment: neurology, oncology, rheumatology, nephrology, psychoneurology, etc.
Sotex’s state-of-the-art and effective medications comply with western clones in terms of quality and are more economical.
A key feature of Sotex’s assortment policy is the orientation toward the production of the widest possible range of dosage forms, dosages and formulations of drugs that enable physicians to optimize and modify drug therapy depending on the needs of an individual patient.
A wide range of dosages and ease of use not only facilitate the work of doctors and nurses, but also enable individual selection of treatment regimens. Thus, making the work of professionals more convenient, the company takes care of the health of patients.
- Own high-tech and innovative pharmaceutical plant in Moscow region
- Portfolio includes 156 SKUs with 122 branded products (30.06.2019)
- Key therapeutic areas: oncology, neurology, rheumatology, nephrology, neuropsychiatry
- Manufacturing capacity: 143 million ampoules and 13 million prefilled syringes annually
- Unique line for manufacturing prefilled syringes with passive needle safety devices
- Annual audits from world leading pharmaceutical manufacturers
- R&D platform with competences of injectable and biotechnological product development
- Exports to 16 countries